Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4

Peter Johansson1, Lauren G Aoude1, Karin Wadt2

  • 1QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Oncotarget
|December 20, 2015
PubMed

Insights

Researchers discovered a new driver mutation, PLCB4 p.D630Y, in uveal melanoma (UM). This gain-of-function mutation activates the same signaling pathway as known UM drivers, suggesting a key role in tumor development.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Uveal melanoma (UM) is the most common primary intraocular malignancy.
  • Previous next-generation sequencing studies identified key driver mutations in GNAQ, GNA11, EIF1AX, SF3B1, and BAP1.

Purpose of the Study:

  • To identify novel driver mutations in uveal melanoma.
  • To investigate the role of PLCB4 mutations in UM tumorigenesis.

Main Methods:

  • Whole-genome and whole-exome sequencing of 28 UM tumors and cell lines.
  • Sanger sequencing for mutation validation.
  • Analysis of published UM sequencing data.

Main Results:

  • A recurrent PLCB4 mutation (p.D630Y) was identified and validated in UM samples.
  • This mutation was mutually exclusive with GNA11 and GNAQ mutations.
  • The PLCB4 mutation signature predominated over UV signatures, suggesting a BRCA-like mutational process.

Conclusions:

  • PLCB4 p.D630Y represents a novel, recurrent, gain-of-function driver mutation in uveal melanoma.
  • This mutation likely activates the same oncogenic signaling pathway as GNA11/GNAQ mutations.
  • The findings provide new insights into UM pathogenesis and potential therapeutic targets.